Financial Review: Pear Therapeutics (NASDAQ:PEAR) and Sema4 (NASDAQ:SMFR)

Pear Therapeutics (NASDAQ:PEARGet Rating) and Sema4 (NASDAQ:SMFRGet Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.


This table compares Pear Therapeutics and Sema4’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pear Therapeutics N/A -289.70% -32.24%
Sema4 N/A -65.87% -34.63%

Analyst Ratings

This is a breakdown of current ratings and target prices for Pear Therapeutics and Sema4, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pear Therapeutics 0 1 4 0 2.80
Sema4 0 0 4 0 3.00

Pear Therapeutics presently has a consensus price target of $11.75, suggesting a potential upside of 194.49%. Sema4 has a consensus price target of $8.60, suggesting a potential upside of 334.34%. Given Sema4’s stronger consensus rating and higher possible upside, analysts plainly believe Sema4 is more favorable than Pear Therapeutics.

Valuation and Earnings

This table compares Pear Therapeutics and Sema4’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pear Therapeutics $4.21 million 130.63 -$65.14 million N/A N/A
Sema4 $212.20 million 2.28 -$245.39 million N/A N/A

Pear Therapeutics has higher earnings, but lower revenue than Sema4.

Institutional and Insider Ownership

53.7% of Pear Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pear Therapeutics Company Profile (Get Rating)

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

Sema4 Company Profile (Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with's FREE daily email newsletter.